Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.39 |
| ▸ | PHGDH | O43175 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522468 | 0.77 | KMT2A (0.47) | MEN1KMT2APROKR1KDM4EMAPT | |
| SCHEMBL22021626 | 0.76 | ACLY (0.47) | ACLYCASP1DRD2 | |
| SCHEMBL29104129 | 0.75 | AHR (0.40) | AHRMCHR1RXFP1MEN1KMT2A | |
| SCHEMBL435737 | 0.72 | RXFP1 (0.47) | AHRACLYRXFP1MEN1KMT2A | |
| SCHEMBL13197458 | 0.71 | PROKR1 (0.42) | MEN1KMT2APROKR1KDM4EMAPT | |
| SCHEMBL8899119 | 0.71 | RXFP1 (0.46) | AHRRXFP1MEN1KMT2APHGDH | |
| SCHEMBL3386079 | 0.71 | RXFP1 (0.46) | AHRRXFP1MEN1KMT2APHGDH | |
| SCHEMBL27764951 | 0.70 | RXFP1 (0.43) | AHRRXFP1MEN1KMT2APHGDH | |
| SCHEMBL28620587 | 0.69 | PROKR1 (0.48) | MEN1KMT2APROKR1KDM4EMAPT | |
| SCHEMBL7799883 | 0.68 | KMT2A (0.50) | AHRACLYRXFP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | AHR 4301/4885ACLY 1/4885MCHR1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.